{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:45:12Z","timestamp":1794469512000,"version":"4.9.1"},"reference-count":105,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2022,6,5]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:p>Topical fluoroquinolones (FQs) are an established treatment for suspected microbial keratitis. An increased FQ resistance in some classes of bacterial pathogens is a concern. Some recently developed FQs have an extended spectrum of activity, making them a suitable alternative for topical ophthalmic use. For example, the new generation FQs, avarofloxacin, delafloxacin, finafloxacin, lascufloxacin, nadifloxacin, levonadifloxacin, nemonoxacin and zabofloxacin have good activity against the common ophthalmic pathogens such as <jats:italic>Staphylococcus aureus<\/jats:italic>, <jats:italic>Pseudomonas aeruginosa<\/jats:italic>, <jats:italic>Streptococcus pneumoniae<\/jats:italic> and several of the <jats:italic>Enterobacteriaceae<\/jats:italic>. However, because there are no published ophthalmic break-point concentrations, the susceptibility of an isolated micro-organism to a topical FQ is extrapolated from systemic break-point data and wild type susceptibility. The purpose of this review is to compare the pharmacokinetics and pharmacodynamics of the FQs licensed for topical ophthalmic use with the same parameters for new generation FQs. We performed a literature review of the FQs approved for topical treatment and the new generation FQs licensed to treat systemic infections. We then compared the minimum inhibitory concentrations (MIC) of bacterial isolates and the published concentrations that FQs achieved in the cornea and aqueous. We also considered the potential suitability of new generation FQs for topical use based on their medicinal properties. Notably, we found significant variation in the reported corneal and aqueous FQ concentrations so that reliance on the reported mean concentration may not be appropriate, and the first quartile concentration may be more clinically relevant. The provision of the MIC for the microorganism together with the achieved lower (first) quartile concentration of a FQ in the cornea could inform management decisions such as whether to continue with the prescribed antimicrobial, increase the frequency of application, use a combination of antimicrobials or change treatment.<\/jats:p>","DOI":"10.1136\/bmjophth-2022-001002","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T11:46:36Z","timestamp":1658144796000},"page":"e001002","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Potential new fluoroquinolone treatments for suspected bacterial keratitis"],"prefix":"10.1136","volume":"7","author":[{"given":"Rose","family":"Herbert","sequence":"first","affiliation":[{"name":"Department of Eye and Vision Science, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Caddick","sequence":"additional","affiliation":[{"name":"Department of Eye and Vision Science, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobi","family":"Somerville","sequence":"additional","affiliation":[{"name":"Department of Eye and Vision Science, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8907-1176","authenticated-orcid":false,"given":"Keri","family":"McLean","sequence":"additional","affiliation":[{"name":"Department of Eye and Vision Science, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakeel","family":"Herwitker","sequence":"additional","affiliation":[{"name":"Pharmacy, Royal Liverpool University Hospital, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Neal","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Royal Liverpool University Hospital, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Czanner","sequence":"additional","affiliation":[{"name":"Applied Mathematics, Liverpool John Moores University, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8192-5192","authenticated-orcid":false,"given":"Stephen","family":"Tuft","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0390-0592","authenticated-orcid":false,"given":"Stephen B","family":"Kaye","sequence":"additional","affiliation":[{"name":"Department of Eye and Vision Science, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"key":"2025090110150954000_7.1.e001002.1","unstructured":"Stapleton F . The epidemiology of infectious keratitis. Ocul Surf (Published Online First: 19 August 2021)."},{"key":"2025090110150954000_7.1.e001002.2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113843","article-title":"A multi-center, cross-sectional study on the burden of infectious keratitis in China","volume":"9","author":"Song","year":"2014","journal-title":"PLoS One"},{"key":"2025090110150954000_7.1.e001002.3","article-title":"Bacterial keratitis: identifying the areas of clinical uncertainty","volume":"101031","author":"Tuft","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"2025090110150954000_7.1.e001002.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30448-5"},{"key":"2025090110150954000_7.1.e001002.5","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.87.7.834"},{"key":"2025090110150954000_7.1.e001002.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.02.030"},{"key":"2025090110150954000_7.1.e001002.7","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-3933"},{"key":"2025090110150954000_7.1.e001002.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.04.021"},{"key":"2025090110150954000_7.1.e001002.9","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161060-00004"},{"key":"2025090110150954000_7.1.e001002.10","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S0002-9394(14)76771-6","article-title":"Conjunctival necrosis after administration of topical fortified aminoglycosides","volume":"111","author":"Davison","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"2025090110150954000_7.1.e001002.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(96)30416-8"},{"key":"2025090110150954000_7.1.e001002.12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1001\/jamaophthalmol.2020.0155","article-title":"Trends in antibiotic resistance among ocular microorganisms in the United States from 2009 to 2018","volume":"138","author":"Asbell","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"2025090110150954000_7.1.e001002.13","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0161-6420(99)00716-2","article-title":"Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review","volume":"106","author":"Goldstein","year":"1999","journal-title":"Ophthalmology"},{"key":"2025090110150954000_7.1.e001002.14","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1016\/j.ophtha.2018.10.018","article-title":"Bacterial keratitis preferred practice Pattern\u00ae","volume":"126","author":"Lin","year":"2019","journal-title":"Ophthalmology"},{"key":"2025090110150954000_7.1.e001002.15","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics11020238","article-title":"Pathogens and antibiotic susceptibilities of global bacterial keratitis: a meta-analysis","volume":"11","author":"Zhang","year":"2022","journal-title":"Antibiotics"},{"key":"2025090110150954000_7.1.e001002.16","doi-asserted-by":"publisher","DOI":"10.1080\/09286580601001347"},{"key":"2025090110150954000_7.1.e001002.17","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e31825694d3"},{"key":"2025090110150954000_7.1.e001002.18","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-308487"},{"key":"2025090110150954000_7.1.e001002.19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7883\/yoken.JJID.2018.269","article-title":"Infectious keratitis: microbiological review of 297 cases","volume":"72","author":"Tena","year":"2019","journal-title":"Jpn J Infect Dis"},{"key":"2025090110150954000_7.1.e001002.20","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/eye.2017.310","article-title":"Microbial keratitis in corneal grafts: predisposing factors and outcomes","volume":"32","author":"Okonkwo","year":"2018","journal-title":"Eye"},{"key":"2025090110150954000_7.1.e001002.21","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41433-019-0463-6","article-title":"An 11-year analysis of microbial keratitis in the South West of England using brain-heart infusion broth","volume":"33","author":"Tavassoli","year":"2019","journal-title":"Eye"},{"key":"2025090110150954000_7.1.e001002.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)01267-3"},{"key":"2025090110150954000_7.1.e001002.23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/ICO.0000000000001423","article-title":"Identification of the infection source of an outbreak of Mycobacterium chelonae keratitis after laser in situ keratomileusis","volume":"37","author":"Nascimento","year":"2018","journal-title":"Cornea"},{"key":"2025090110150954000_7.1.e001002.24","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-312881"},{"key":"2025090110150954000_7.1.e001002.25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/tvst.9.13.2","article-title":"16S ribosomal RNA PCR versus conventional diagnostic culture in the investigation of suspected bacterial keratitis","volume":"9","author":"Somerville","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"2025090110150954000_7.1.e001002.26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2017-000086","article-title":"Microbial keratitis and the selection of topical antimicrobials","volume":"1","author":"Kaye","year":"2017","journal-title":"BMJ Open Ophthalmol"},{"key":"2025090110150954000_7.1.e001002.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.11.004"},{"key":"2025090110150954000_7.1.e001002.28","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.9.1229"},{"key":"2025090110150954000_7.1.e001002.29","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis189"},{"key":"2025090110150954000_7.1.e001002.30","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4638"},{"key":"2025090110150954000_7.1.e001002.31","unstructured":"GMC . Prescribing unlicensed medicines, 2021. Available: https:\/\/www.gmc-uk.org\/ethical-guidance\/ethical-guidance-for-doctors\/good-practice-in-prescribing-and-managing-medicines-and-devices\/prescribing-unlicensed-medicines [Accessed Dec 2021]."},{"key":"2025090110150954000_7.1.e001002.32","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00070-19","article-title":"Practical guidance for clinical microbiology laboratories: diagnosis of ocular infections","volume":"34","author":"Leal","year":"2021","journal-title":"Clin Microbiol Rev"},{"key":"2025090110150954000_7.1.e001002.33","unstructured":"GOV.UK . Uk standards for microbiology investigations (UK SMI): general information. Available: http:\/\/www.hpa.org.uk\/SMI\/pdf [Accessed 20 Jan 2022]."},{"key":"2025090110150954000_7.1.e001002.34","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.5.1298"},{"key":"2025090110150954000_7.1.e001002.35","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics6020011","article-title":"Erythromycin modification that improves its acidic stability while optimizing it for local drug delivery","volume":"6","author":"Cyphert","year":"2017","journal-title":"Antibiotics"},{"key":"2025090110150954000_7.1.e001002.36","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl489"},{"key":"2025090110150954000_7.1.e001002.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2014.04.048"},{"key":"2025090110150954000_7.1.e001002.38","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-3201"},{"key":"2025090110150954000_7.1.e001002.39","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0002-9394(42)91317-5","article-title":"Factors affecting penetration of drugs into the cornea","volume":"25","author":"Swan","year":"1942","journal-title":"Am J Ophthalmol"},{"key":"2025090110150954000_7.1.e001002.40","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.46005-0"},{"key":"2025090110150954000_7.1.e001002.41","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1021\/jm01240a021","article-title":"1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents","volume":"91","author":"Lesher","year":"1962","journal-title":"J Med Pharm Chem"},{"key":"2025090110150954000_7.1.e001002.42","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13081289","article-title":"Structural Characterization of the Millennial Antibacterial (Fluoro)Quinolones-Shaping the Fifth Generation","volume":"13","author":"Rusu","year":"2021","journal-title":"Pharmaceutics"},{"key":"2025090110150954000_7.1.e001002.43","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0002-9394(14)74449-6","article-title":"Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis","volume":"115","author":"Parks","year":"1993","journal-title":"Am J Ophthalmol"},{"key":"2025090110150954000_7.1.e001002.44","doi-asserted-by":"publisher","DOI":"10.1039\/c9md00120d"},{"key":"2025090110150954000_7.1.e001002.45","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/S0161-6420(97)30009-8","article-title":"Ofloxacin monotherapy for the primary treatment of microbial keratitis: a double-masked, randomized, controlled trial with conventional dual therapy. The ofloxacin Study Group","volume":"104","year":"1997","journal-title":"Ophthalmology"},{"key":"2025090110150954000_7.1.e001002.46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/OPTH.S1666","article-title":"Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections","volume":"2","author":"Miller","year":"2008","journal-title":"Clin Ophthalmol"},{"key":"2025090110150954000_7.1.e001002.47","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464200-00006"},{"key":"2025090110150954000_7.1.e001002.48","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-306502"},{"key":"2025090110150954000_7.1.e001002.49","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.survophthal.2005.07.001","article-title":"Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans","volume":"50 Suppl 1","author":"Robertson","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"2025090110150954000_7.1.e001002.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2004.09.029"},{"key":"2025090110150954000_7.1.e001002.51","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3181ca2ba3"},{"key":"2025090110150954000_7.1.e001002.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.12.011"},{"key":"2025090110150954000_7.1.e001002.53","doi-asserted-by":"publisher","DOI":"10.3109\/09286586.2013.790978"},{"key":"2025090110150954000_7.1.e001002.54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40123-016-0046-6","article-title":"Besifloxacin: efficacy and safety in treatment and prevention of ocular bacterial infections","volume":"5","author":"Mah","year":"2016","journal-title":"Ophthalmol Ther"},{"key":"2025090110150954000_7.1.e001002.55","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn528"},{"key":"2025090110150954000_7.1.e001002.56","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-012-0027-7"},{"key":"2025090110150954000_7.1.e001002.57","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/10408347.2018.1429885","article-title":"Besifloxacin: a critical review of its characteristics, properties, and analytical methods","volume":"48","author":"T\u00f3toli","year":"2018","journal-title":"Crit Rev Anal Chem"},{"key":"2025090110150954000_7.1.e001002.58","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm398"},{"key":"2025090110150954000_7.1.e001002.59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237603","article-title":"Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6","volume":"15","author":"DeCory","year":"2020","journal-title":"PLoS One"},{"key":"2025090110150954000_7.1.e001002.60","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s40261-020-00953-z","article-title":"Community-Acquired bacterial Pneumonia-Changing epidemiology, resistance patterns, and newer antibiotics: spotlight on Delafloxacin","volume":"40","author":"Sharma","year":"2020","journal-title":"Clin Drug Investig"},{"key":"2025090110150954000_7.1.e001002.61","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx543"},{"key":"2025090110150954000_7.1.e001002.62","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1079"},{"key":"2025090110150954000_7.1.e001002.63","doi-asserted-by":"crossref","DOI":"10.1186\/s12941-016-0150-4","article-title":"Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin","volume":"15","author":"Kocsis","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2025090110150954000_7.1.e001002.64","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01201-10"},{"key":"2025090110150954000_7.1.e001002.65","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s40265-020-01358-0","article-title":"Delafloxacin: a review in acute bacterial skin and skin structure infections","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"2025090110150954000_7.1.e001002.66","doi-asserted-by":"crossref","DOI":"10.1186\/s12348-020-0200-0","article-title":"In vitro susceptibilities of methicillin-susceptible and resistant staphylococci to traditional antibiotics compared to a novel fluoroquinolone","volume":"10","author":"Fan","year":"2020","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"2025090110150954000_7.1.e001002.67","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.2147\/DDDT.S229882","article-title":"Levonadifloxacin, a novel broad-spectrum anti-MRSA benzoquinolizine quinolone agent: review of current evidence","volume":"13","author":"Bhagwat","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"2025090110150954000_7.1.e001002.68","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.9.3338-3342.2004"},{"key":"2025090110150954000_7.1.e001002.69","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2004.01017.x"},{"key":"2025090110150954000_7.1.e001002.70","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.12.4754-4761.2004"},{"key":"2025090110150954000_7.1.e001002.71","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01348-18","article-title":"In Vitro Activities of the Benzoquinolizine Fluoroquinolone Levonadifloxacin (WCK 771) and Other Antimicrobial Agents against Mycoplasmas and Ureaplasmas in Humans, Including Isolates with Defined Resistance Mechanisms","volume":"62","author":"Xue","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025090110150954000_7.1.e001002.72","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01150-08"},{"key":"2025090110150954000_7.1.e001002.73","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.3188-3192.2004"},{"key":"2025090110150954000_7.1.e001002.74","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00084-20","article-title":"Levonadifloxacin, a novel benzoquinolizine fluoroquinolone, modulates lipopolysaccharide-induced inflammatory responses in human whole-blood assay and murine acute lung injury model","volume":"64","author":"Patel","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025090110150954000_7.1.e001002.75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jdermsci.2005.01.002","article-title":"Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes","volume":"38","author":"Kuwahara","year":"2005","journal-title":"J Dermatol Sci"},{"key":"2025090110150954000_7.1.e001002.76","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1177\/1060028018786510","article-title":"Ozenoxacin: a novel topical quinolone for impetigo","volume":"52","author":"Wren","year":"2018","journal-title":"Ann Pharmacother"},{"key":"2025090110150954000_7.1.e001002.77","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.3.455"},{"key":"2025090110150954000_7.1.e001002.78","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jgar.2020.10.017","article-title":"Tentative clinical breakpoints and epidemiological cut-off values of nemonoxacin for Streptococcus pneumoniae and Staphylococcus aureus isolates associated with community-acquired pneumonia","volume":"23","author":"Jean","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2025090110150954000_7.1.e001002.79","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01374-09"},{"key":"2025090110150954000_7.1.e001002.80","doi-asserted-by":"crossref","unstructured":"Barnes KB , Zumbrun SD , Halasohoris SA . Demonstration of the broad spectrum in vitro activity of finafloxacin against pathogens of biodefence interest. Antimicrob Agents Chemother;63:e01470.doi:10.1128\/AAC.01470-19","DOI":"10.1128\/AAC.01470-19"},{"key":"2025090110150954000_7.1.e001002.81","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00077-17","article-title":"Antibiotic hybrids: the next generation of agents and adjuvants against gram-negative pathogens?","volume":"31","author":"Domalaon","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"2025090110150954000_7.1.e001002.82","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025320","article-title":"Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance","volume":"6","author":"Hooper","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2025090110150954000_7.1.e001002.83","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2014.04.007"},{"key":"2025090110150954000_7.1.e001002.84","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12830"},{"key":"2025090110150954000_7.1.e001002.85","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)07322-4"},{"key":"2025090110150954000_7.1.e001002.86","doi-asserted-by":"publisher","DOI":"10.1086\/338571"},{"key":"2025090110150954000_7.1.e001002.87","unstructured":"ESCMID-European Society of Clinical Microbiology . Diseases I. [No title]. Available: https:\/\/www.eucast.org\/clinical_breakpoints\/ [Accessed 01 Feb 2022]."},{"key":"2025090110150954000_7.1.e001002.88","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000248379.78777.f6"},{"key":"2025090110150954000_7.1.e001002.89","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(94)00087-D"},{"key":"2025090110150954000_7.1.e001002.90","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00162-11"},{"key":"2025090110150954000_7.1.e001002.91","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/BF02849853","article-title":"Antibacterial activity of the fourth-generation fluoroquinolones gatifloxacin and moxifloxacin against ocular pathogens","volume":"20","author":"Callegan","year":"2003","journal-title":"Adv Ther"},{"key":"2025090110150954000_7.1.e001002.92","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3325-3333.2005"},{"key":"2025090110150954000_7.1.e001002.93","unstructured":"ESCMID-European Society of Clinical Microbiology . Infectious diseases. EUCAST: clinical breakpoints and dosing of antibiotics. Available: https:\/\/www.eucast.org\/clinical_breakpoints\/ [Accessed 18 Apr 2022]."},{"key":"2025090110150954000_7.1.e001002.94","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.3.802-805.2000"},{"key":"2025090110150954000_7.1.e001002.95","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00941-16"},{"key":"2025090110150954000_7.1.e001002.96","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00833-10"},{"key":"2025090110150954000_7.1.e001002.97","unstructured":"Ciloxan 0.3% w\/v eye drops solution. Available: https:\/\/www.medicines.org.uk\/emc\/product\/836\/smpc [Accessed 19 Apr 2022]."},{"key":"2025090110150954000_7.1.e001002.98","unstructured":"Levofloxacin 5mg\/ml eye drops solution. Available: https:\/\/www.medicines.org.uk\/emc\/product\/7357\/smpc [Accessed 19 Apr 2022]."},{"key":"2025090110150954000_7.1.e001002.99","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01407-05"},{"key":"2025090110150954000_7.1.e001002.100","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp370"},{"key":"2025090110150954000_7.1.e001002.101","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks307"},{"key":"2025090110150954000_7.1.e001002.102","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl304"},{"key":"2025090110150954000_7.1.e001002.103","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00078-09"},{"key":"2025090110150954000_7.1.e001002.104","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00295-10"},{"key":"2025090110150954000_7.1.e001002.105","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4839"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2022-001002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T17:15:24Z","timestamp":1756746924000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2022-001002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":105,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,7,18]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/bmjophth-2022-001002"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2022-001002","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}